Citius Pharmaceuticals (CTXR) Research & Development (2013 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Research & Development came in at $1.6 million in Q1 2026, down 56.63% YoY from $3.8 million in Q1 2025, and up 2.11% on a QoQ basis from $1.6 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Research & Development (2013 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 14 years of Research & Development data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Research & Development fell 56.63% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 43.86% YoY) and the FY2025 annual result came in at $9.2 million, down 23.1% from the prior year.
- Research & Development rose to $1.6 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $4.9 million in Q2 2022 to a low of $1.6 million in Q4 2025.
- A 5-year average of $3.0 million and a median of $2.9 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 122.53% — and 2026, when it plunged 56.63%.
- Tracing CTXR's Research & Development over 5 years: stood at $3.4 million in 2022, then dropped by 23.9% to $2.6 million in 2023, then slipped by 18.87% to $2.1 million in 2024, then declined by 24.79% to $1.6 million in 2025, then gained by 2.11% to $1.6 million in 2026.
- The last three Research & Development figures came in at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | 3.61 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 3.76 Mn |
| Mar 31, 2023 | 4.73 Mn |
| Dec 31, 2022 | 3.45 Mn |
| Sep 30, 2022 | 3.86 Mn |
| Jun 30, 2022 | 4.89 Mn |
| Mar 31, 2022 | 3.45 Mn |
| Dec 31, 2021 | 5.46 Mn |
| Sep 30, 2021 | 5.00 Mn |
| Jun 30, 2021 | 2.20 Mn |